| 2026-10-26 17:04 |
8-K |
["8.01", "9.01"] |
other |
0.15
|
Reverse stock split announcement (1:10 ratio); no M&A signals present. |
SEC · detail |
| 2026-10-23 11:40 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
Routine loan advance to third party; no M&A indicators despite Rule 14a-12 box check. |
SEC · detail |
| 2026-09-14 10:39 |
8-K |
["1.01", "7.01", "9.01"] |
merger agreement |
0.85
|
Onconetix entering material definitive Share Exchange Agreement to acquire Realbotix equity interests; financing loan indicates active M&A progression. |
SEC · detail |
| 2026-07-29 17:02 |
8-K |
["1.01"] |
material agreement |
0.15
|
PIPE financing round with Series F convertible preferred stock; financing agreement unrelated to M&A or acquisition activity. |
SEC · detail |
| 2026-05-19 16:05 |
8-K |
["5.03", "8.01", "9.01"] |
other |
0.05
|
Reverse stock split to maintain Nasdaq compliance; no M&A signals present. |
SEC · detail |
| 2026-05-13 20:35 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
Routine operational update on subsidiary's clinical progress; no M&A signals detected. |
SEC · detail |
| 2026-05-04 16:05 |
8-K |
["5.07", "9.01"] |
other |
0.15
|
Reverse stock split approval voted on; no M&A transaction indicated. |
SEC · detail |
| 2026-04-24 16:32 |
8-K |
["5.02", "9.01"] |
officer change |
0.62
|
Board turnover with M&A-experienced executive (Epstein) appointed; weak but suggestive of strategic review. |
SEC · detail |